Table 3

Sensitivity analyses of AKI in Mount Sinai and Geisinger propensity-matched cohort

Mount Sinai cohortGeisinger cohort
Unadjusted (95% CI)Adjusted (95% CI)Unadjusted (95% CI)Adjusted (95% CI)
Using AKIKDIGO definition0.4 (0.2–0.7)0.4 (0.2–0.7)0.5 (0.3–0.8)0.6 (0.4–1.1)
Using AKI ICD codes0.5 (0.3–0.8)0.5 (0.3–0.9)0.43 (0.23–0.79)0.56 (0.27–1.16)
User/nonusers not missing any covariate data0.7 (0.3–1.3)0.7 (0.3–1.4)0.70 (0.37–1.33)0.81 (0.40–1.66)
Canagliflozin0.2 (0.1–0.5)0.2 (0.1–0.5)0.54 (0.32–0.93)0.61 (0.33–1.12)
Dapagliflozin1.0 (0.5–2.4)1.1 (0.5–2.7)0.16 (0.02–1.33)0.32 (0.02–5.18)
EmpagliflozinNANA0.50 (0.15–1.66)0.96 (0.21–4.35)
  • Results for empagliflozin in Mount Sinai cohort not available (NA) because of small sample size and lack of model convergence.